Scribe Therapeutics made a striking debut on Nasdaq, raising $128.7 million and seeing its stock soar 67% on the first trading day. The company priced its shares at $15 each, hitting the upper limit of its range, and sold a total of 8.58 million shares under the ticker SCTX.
What Scribe's Technology Brings to the Table
Founded between 2017 and 2018, Scribe Therapeutics emerged from UC Berkeley’s Doudna Lab with a unique focus on gene silencing via epigenetic modulation. Unlike traditional CRISPR methods that permanently alter DNA sequences, Scribe’s platform temporarily quiets specific genes without changing the DNA itself.
Their lead drug candidate, STX-1150, is currently in Phase 1 clinical trials aiming to lower LDL cholesterol. Another program, STX-1200, is in preclinical development targeting lipoprotein(a) reduction. Early data for STX-1200 showed it could cut Lp(a) levels by more than 90% in model systems, a promising result given the link between Lp(a) and cardiovascular risk.
Investments and Industry Partnerships Fuel Momentum
Scribe’s initial funding rounds included a $20 million injection from venture giant Andreessen Horowitz. By March 2026, the biotech had roughly $50 million in cash reserves. on top of that, Scribe has forged strategic alliances with major pharmaceutical companies such as Biogen, Sanofi, and Eli Lilly. These collaborations provide upfront milestone payments and future royalty opportunities, offering revenue streams before the company brings products to market.
Though Scribe increased its IPO size to match demand, the company remains in early clinical stages. The lead candidate’s Phase 1 status means years of testing and regulatory hurdles remain. Investors who bought shares after the IPO are paying a notable premium compared to initial buyers.
